The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC74647 in HCV-infected Subjects

Inclusion Criteria: * Able to comprehend and sign the ICF voluntarily prior to initiate the study; * Able to complete the study according to the protocol; * Agree to use protocol defined precautions against pregnancy * Body weight of male and female subject should be ≥50 kg and ≥45 kg respectively; Body Mass Index (BMI) is between 18 and 30 kg/m2, inclusive; * HCV treatment-naïve adult subjects with GT1-6 HCV infection * HCV RNA level ≥ 5 log10 IU/mL at screening * FibroScan score within 6 months≤12.5 kPa or Liver biopsy results within 12 months proved Non-cirrhosis Exclusion Criteria: * Smokers, who smoke more than 5 cigarettes/day within 3 months before the study; * Drink frequently, namely alcohol consumption are 14 units per week (1 unit = 285 mL of beer, or 25 mL of strong wine, or 100 mL of grape wine); * Donated blood or massive blood loss within 3 months before screening (\>450 mL）; * Have any disease that increases the risk of bleeding, such as acute gastritis or stomach and duodenal ulcers; * Have taken any prescription drug, over-the-counter drug, vitamin product or herbal medicine within 14 days prior to screening; * Have taken any drug that inhibit gastric acid secretion, such as H2 receptor antagonist famotidine and proton pump inhibitor omeprazole; * Have participated in any clinical trial or taken any study drug within 3 months before dosing; * Positive test result of HBV,HIV or syphilis; * Solid organ transplanters